Home
Products
Cirsilineol
| Product Name | Cirsilineol |
| Price: | Inquiry |
| Catalog No.: | CN05170 |
| CAS No.: | 41365-32-6 |
| Molecular Formula: | C18H16O7 |
| Molecular Weight: | 344.32 g/mol |
| Purity: | >=98% |
| Type of Compound: | Flavonoids |
| Physical Desc.: | Yellow powder |
| Source: | The herbs of Artemisia capillaries |
| Solvent: | Chloroform, Dichloromethane, Ethyl Acetate, DMSO, Acetone, etc. |
| SMILES: | COc1cc2oc(cc(=O)c2c(c1OC)O)c1ccc(c(c1)OC)O |
| Contact us | |
|---|---|
| First Name: | |
| Last Name: | |
| E-mail: | |
| Question: | |
| Description | Cirsilineol, a natural flavone compound, selectively inhibits IFN-γ/STAT1/T-bet signaling in intestinal CD4+ T cells. Cirsilineol has potent immunosuppressive and anti-tumor properties. Cirsilineol significantly ameliorates trinitro-benzene sulfonic acid (TNBS)-induced T-cell-mediated experimental colitis in mice[1]. |
| In Vitro | Cirsilineol (0.1-10 μM; 96 hours) single mixed lymphocyte reaction and Con A-induced T-cell proliferation in a dose-dependent manner. Cirsilineol (10 μM) does not affect T lymphocyte's viability. The inhibition of cirsilineol (10 μM) on T-cell proliferation is not due to a cytotoxic activity[1]. Cirsilineol (1-10 μM; pretreatment for 3 hours) completely inhibits IFN-γ-induced Tyr701 phosphorylation of STAT1 and JAK2 activation[1]. Cell Proliferation Assay[1] Cell Line: Splenocytes Concentration: 0.1, 1, 10 μM Incubation Time: 96 hours Result: Inhibited single mixed lymphocyte reaction and Concanavalin A (Con A; 5 μg/mL; for 72 h)-induced T-cell proliferation in a dose-dependent manner. Suppressed OVA323-339-specific CD4+ T-cell proliferation. Western Blot Analysis[1] Cell Line: Splenic CD4+ T cells Concentration: 1, 5, 10 μM Incubation Time: Pretreatment for 3 hours Result: Completely inhibited IFN-γ-induced (25 ng; 30 mins) Tyr701 phosphorylation of STAT1 and JAK2 activation. Suppressed IFN-γ-induced (25 ng; 12 hours) Th1-specific transcription factor T-bet. |
| In Vivo | cirsilineol (3, 10, and 30 mg/kg) significantly ameliorates TNBS-induced Th1-mediated colitis through inhibiting IFN-γ/STAT1/T-bet signaling in CD4+ T cells. Animal Model: 8-10-week-old female C57BL/6, BALB/c and DO11.10 transgenic mice with TNBS (10 mg; 100 μL)[1] Dosage: 3, 10, 30 mg/kg Administration: IP; daily; for 11 days Result: Showed a significant improved effect on the body weights and survival rate of mice. Markedly reduced inflammatory infiltration, restoration of the destructive mucosal architecture and remission of edema. |
| Density | 1.387g/cm3 |
| Boiling Point | 585ºC at 760 mmHg |
| Flash Point | 215.2ºC |
| Exact Mass | 344.09000 |
| PSA | 98.36000 |
| LogP | 2.89700 |
| Storage condition | ?20°C |